Travaux scientifiques

Uzm. Dr. Duygu Özaşkın

14 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Palliative Care Awareness Among Caregivers of Cancer Patients in Turkey: A Cross-Sectional Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33080458 PMID 42645362 Texte intégral en libre accèsSource : OpenAlex

  2. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Texte intégral en libre accèsSource : Europe PMC

  3. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-026-04228-5 PMID 41670816 Source : Europe PMC

  4. Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy—A Real-World Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33070381 PMID 42505183 Texte intégral en libre accèsSource : ORCID

  5. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62030538 PMID 41901620 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  6. ARE mGPS, SIS, AND LCS SIGNIFICANT IN PREDICTING FIRST-LINE PALLIATIVE CHEMOTHERAPY RESPONSE AND PROGNOSIS IN PATIENTS WITH METASTATIC GASTRIC CANCER?

    Zenodo (CERN European Organization for Nuclear Research), 2026

    DOI 10.5281/zenodo.18936420 Texte intégral en libre accèsSource : OpenAlex

  7. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

    Discover Oncology, 2025

    DOI 10.1007/s12672-025-03886-1 PMID 41249604 Texte intégral en libre accèsSource : OpenAlex

  8. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70212 PMID 41147691 Source : OpenAlex

  9. HEREDITARY COLORECTAL CANCER SYNDROMES

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-770-4_p17 Source : OpenAlex

  10. Metastatik Meme Kanserinde Birinci Basamak Tedavi Sonuçlarının Değerlendirilmesi

    Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 2025

    DOI 10.17517/ksutfd.1341433 Texte intégral en libre accèsSource : ORCID

  11. Frequency of Thyroid Nodules and Autoimmune Thyroid Disease in Patients with Adrenal Incidentaloma

    Eurasian Journal of Medical Advances, 2025

    DOI 10.14744/ejma.267174 Texte intégral en libre accèsSource : OpenAlex

  12. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

    Breast Cancer Research and Treatment, 2024

    DOI 10.1007/s10549-024-07456-x PMID 39123071 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  13. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. Comparison of clinicopathological and prognostic features of breast cancer patients younger than 40 years and older than 65 years

    Discover oncology, 2024

    DOI 10.1007/s12672-024-00952-y PMID 38649531 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID